newsfilter
← Latest News
GlobeNewswire·

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion's cash runway to first half of 2027 MSD will assume full responsibility for the further development of EVX-B3 with Evaxion eligible